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Abstract
Background: Pollen-induced allergic rhinoconjunctivitis (AR) is highly prevalent and
rapidly evolving during childhood. General practitioners may not be fully aware of the
nature and severity of symptoms experienced by patients and might underestimate the
prevalence of moderate or severe disease. Thus, the relevance of early diagnosis and
intervention may be overlooked.
Objectives: To investigate the severity of pollen-induced AR and its determinants in
Italian children referred to allergy specialists and who had never received specific
immunotherapy (SIT).
Methods: Children (age 4–18 yr) affected by pollen-induced AR who had never
undergone SIT were recruited between May 2009 and June 2011 in 16 pediatric
outpatient clinics in 14 Italian cities. Recruited children’s parents answered standard-
ized questionnaires on atopic diseases (International Study of Allergy and Asthma in
Childhood, Allergic Rhinitis and its Impact on Asthma, Global Initiative for Asthma).
The children underwent skin-prick test (SPT) with several airborne allergens and six
food allergens. Information on socio-demographic factors, parental history of allergic
diseases, education, perinatal events, breastfeeding, nutrition and environmental
exposure in early life was collected through an informatics platform shared by the
whole network of clinical centers (AllergyCARDTM).
Results: Among the 1360 recruited patients (68% males, age 10.5  3.4 yr), 695
(51%) had moderate-to-severe AR, 533 (39%) asthma, and 325 (23.9%) oral allergy
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syndrome (OAS). Reported onset of pollen-induced AR was on average at
5.3  2.8 yr, and its mean duration from onset was 5.2  3.3 yr. Only 6.2% of the
patients were pollen-monosensitized, and 84.9% were sensitized to ≥3 pollens. A
longer AR duration was significantly associated with moderate-to-severe AR
symptoms (p 0.004), asthma (p 0.030), and OAS comorbidities (p < 0.001).
Conclusions: This nationwide study may raise awareness of the severity of pollen-
induced AR among Italian children who have never received pollen SIT. The strong
association between pollen-induced AR duration and several markers of disease
severity needs replication in longitudinal studies, while suggesting that countrywide
initiatives for earlier diagnosis and intervention should be planned.
Allergic rhino-conjunctivitis (AR) induced by pollens (pollen-
induced AR) is a very common allergic disease, affects
millions of people globally (1), and is particularly prevalent
among children (2). Patients’ performance of daily activities,
sleep patterns, cognitive function, work and school produc-
tivity, and quality of life are impaired (3). Less than half of
the patients seek medical advice, and drug therapies generally
achieve only partial control of symptoms (3). Specific immu-
notherapy (SIT) with pollen extracts can reduce symptoms
and prevent subsequent asthma and is the only intervention
that might modify the natural history of pollen-induced AR if
properly and timely administered (4). Nevertheless, only a
minority of eligible patients receive SIT (5). Recently, a pan-
European survey demonstrated that (primary health) physi-
cians may not be fully aware of the nature and severity of
symptoms experienced by patients and that they often
underestimate the prevalence of moderate or severe disease
(3). The reasons for such suboptimal management of pollen
AR may change in different countries, and the local condi-
tions should be examined. Unfortunately, countrywide epide-
miological data on pollen-induced AR are scarce in most
European countries, and information on the level of AR
severity of the patients seen by allergy specialists is missing.
To fill this gap, we investigated children referred to allergy
specialists in Italy and who had never received SIT for their
pollen-induced AR. To this end, we have used the ‘Panaller-
gens in Pediatrics’ (PAN-PED) survey, a multicenter, coun-
trywide study performed by the Italian Pediatric Allergy
Network (I-PAN; 6, 7). Results of a pilot study of this
project, focused on molecular aspects of IgE sensitization in
200 children living in Rome, have recently been published (8).
Here, we report the analysis of the determinants of pollen-
induced AR severity in the whole population sample of 1360
children recruited by 16 I-PAN centers from 14 cities widely
distributed across the country.
Materials and methods
Study population and study design
Panallergens in Pediatrics (PAN-PED) is the first nationwide
observational multicenter survey carried out by the I-PAN.
I-PAN is a large group of Italian specialists in Pediatric
Allergy, sharing informatics technology and acquiring useful
scientific information from routine clinical practice (6, 7). The
study aims at investigating the impact of sensitization to highly
cross-reacting allergenic molecules on the diagnostic and
therapeutic management of respiratory allergies in childhood.
Children spontaneously seeking care were enrolled in 16
pediatric outpatient clinics in 14 Italian cities in Northern
Italy (five centers: Milan, Genoa, Verona, Parma and Bolo-
gna), Central Italy (five centers: Empoli, Ascoli Piceno, Ostia
and three in Rome), and Southern Italy (five centers: Naples,
Benevento, Crotone, Cagliari and Palermo) between May 2009
and June 2011. Criteria for eligibility were as follows: (i) age 4–
18 yr; (ii) a history of pollen-induced AR and/or asthma in one
of the two last pollen seasons; (iii) positive skin-prick tests
(SPT) for the relevant pollen extracts. Exclusion criteria were
as follows: (i) previous SIT for any pollen allergen; (ii) any
other severe chronic disease. Recruited children’s parents
answered a standardized questionnaire, and patients under-
went SPT and a blood drawing. For the present analysis, only
results obtained through the questionnaire and SPT in patients
with AR have been considered. The PAN-PED study design
and procedures have been approved by the ethical committee
of all the participating centers. Parents or tutors of all
participants gave an informed written consent to clinical
investigations.
Questionnaire and diagnostic criteria
Questions obtained from the following internationally vali-
dated questionnaires were administered to all participants:
International Study of Allergy and Asthma in Childhood
(ISAAC; 9), Allergic Rhinitis and its Impact on Asthma
(ARIA; 10), and Global Initiative for Asthma (GINA; 11). A
diagnosis of pollen-induced AR was made as previously
described (8) in the presence of: (i) nasal and/or eye symptoms
(apart from cold) (9) for at least 3 weeks during one of the two
last pollen seasons and (ii) positive SPT (wheal reaction of
Abbreviations
ANOVA, analysis of variance; AR, allergic rhinitis; ARIA, Allergic Rhinitis
and its Impact on Asthma; CI, confidence interval; GINA, Global
Initiative for Asthma; I-PAN, Italian Pediatric Allergy Network; ISAAC,
International Study of Allergy and Asthma in Childhood; OAS, oral
allergy syndrome; PAN-PED, Panallergens in Pediatrics; SD, standard
deviation; SIT, specific immunotherapy; SPT, skin-prick test.
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3 mm or more) in accordance with clinical history and local
pollination period. Pollen-induced AR was classified as mild or
moderate/severe as well as intermittent or persistent according
to the ARIA classification (10). Children with pollen-induced
AR were also classified as sneezers or blockers (or unclassified)
according to the same ARIA classification (10). The age at
onset of pollen-induced AR was reported by the parents as
their child’s age at the first season with relevant symptoms. The
duration of AR since its onset was established as the difference
in years between the child’s age at recruitment and the child’s
age at AR onset. The annual period of symptoms was defined
as the months with symptoms in the 12 months preceding the
recruitment visit. Asthma was classified as intermittent, mild
persistent, moderate persistent, or severe persistent according
to the GINA classification (12). Oral allergy syndrome (OAS)
was defined as the occurrence of immediate oral itching with or
without angioedema of the lips and or the tongue following the
ingestion of the food (13). Reported immediate reaction to
foods was defined by a positive answer to the following
question: ‘Have/has you/your child ever had immediate allergic
reaction after ingestion of…?’ Questions regarding socio-
demographic factors, family history of allergic diseases, edu-
cation, perinatal events, breast feeding and nutrition, and
environmental exposure (tobacco smoke) in early life were
asked. An informatics platform (‘AllergyCARDTM,’ Technol-
ogy Projects & Software Productions [TPS], Rome, Italy) was
used for data input.
Skin-prick tests
SPT were performed using a standard panel of commercial
extracts (ALK-Abello, Milan, Italy) of seasonal airborne
allergens (Phleum pratense, Cynodon dactylon, pellitory, Plan-
tago lanceolata, Chenopodium album, mugwort, Salsola kali,
ragweed, cypress, birch, plane, Olea europaea, elm, hazel), food
allergens (peach, apple, wheat, soybean, peanut, hazelnut), and
latex. A commercial date palm pollen extract enriched in
profilin (ALK-Abello) was used to detect profilin sensitization
(13). Histamine 0.1 mg/ml and glycerol solution were used as
positive and negative controls, respectively. Morrow-Brown
needles were used to prick the skin, and the wheal reactions
were read after 15 min. A wheal ≥3 mm after subtraction of the
negative control was regarded as positive (14). Polysensitiza-
tion to pollen allergens was defined as a positive response to at
least three pollen allergenic sources.
Statistics
Data were summarized as numbers (n) and frequencies (%) if
datawere categorical and asmean and standarddeviation (SD) if
data were quantitative. Patients were grouped in three geo-
graphic areas (North, Center, South) depending on the geo-
graphic position of their recruitment center. Chi-square and
analysis of variance (ANOVA) were used to evaluate differences
between the three geographic areas when data were categorical
or quantitative, respectively. Chi-square was also used to
compare, among children with pollen AR, those with asthma
vs. those without asthma and those with AR vs. those without
AR, if data were categorical; if data were quantitative, Student’s
t-test was used. Two different multiple stepwise logistic regres-
sions were applied to evaluate possible risk factors for a more
severeAR, defined by amoderate-to-severe ARIA classification,
by asthma and by OAS comorbidity. Only factors associated at
univariate level (p < 0.10) were included in this model. Adjusted
odds ratio (OR) and its 95% confidence interval (95% CI) were
calculated. A p-value <0.05 was considered statistically signif-
icant. STATA 12.1 (StataCorp LP, College Station, Texas,
USA) was used for all analyses.
Results
Study population and risk factors
A total of 1360 patients (68% males, mean age 10.5  3.4)
were recruited, 405 of whom (30%) from Northern Italy, 672
(49%) from Central Italy and 283 (21%) from Southern Italy.
The vast majority (96%) of the children were born from
Italian, Caucasian parents. About one-fourth of the patients
were only children, and 37% had older siblings. A history of
atopic diseases in the biologic father or mother was reported by
529 (39%) and 602 (44%) of the patients, respectively. Only
5% of the mothers had smoked during pregnancy, while 538
(40%) of the fathers and 314 (23%) of the mothers were
current smokers (Table 1).
Characteristics of pollen AR
The mean age at onset of pollen-induced AR was 5.3 yr
(SD  2.8), and the mean disease duration since onset was
5.2 yr (SD  3.3). Altogether, 994 (73%) of the patients
reported that their AR had started at least 3 yr before, and 436
(32%) reported at least 7 yr before (Fig. 1a). According to the
ARIA classification, 875 (64%) AR patients were ‘sneezers,’
and 169 (12%) were ‘blockers,’ while for the remaining 316
(23%) children, no category could be assigned. AR was mild in
49% (665) of the patients, whereas a moderate-to-severe form
was observed in 695 (51%). As expected, most patients had AR
symptoms during spring and a smaller proportion in early
autumn (Fig. 1b). Overall, 533 patients (39%) had asthma
comorbidity. Among the group of 533 asthmatic patients, the
mean age at onset of asthma was 5.0 yr (SD  3.1). Intermit-
tent asthma was the most frequent category of asthma, while
only 33 children (2%) were affected by severe asthma. Asthma
was uncontrolled in 217 patients, partially controlled in 225,
and well controlled in only 116 patients (Table 1).
Allergic symptoms to plant-derived foods
OASwas reported by 325 (24%) of the patients. About one-third
and one-fifth of the patients reported a history of atopic
dermatitis and urticaria/angioedema, respectively. Anaphylaxis
was reported by 77 (6%) patients (Table 1). Allergic reactions
triggered by a plant-derived food were reported by 384 (28%)
patients. The plant-derived foodmost frequently reported to be a
cause of allergic reactions was kiwi, followed byRosaceae (peach
and apple) and nuts (hazelnut, peanut, and walnut) (Fig. 1c).
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Sensitization to pollens and food allergens
The vast majority of the patients were polysensitized
(Fig. 1d). Pollen monosensitization was observed in 6.2% of
the patients, while 84.9% and 52.9% of them were sensitized
to at least 3 or 6 pollen extracts, respectively (Table 2,
Fig. 1d). The vast majority of the patients (89%) were
sensitized to timothy grass (Phleum pratense). Sensitization to
olive tree pollen was also very frequent (60%), while 37%,
34%, and 22% were sensitized to birch, pellitory, and
ragweed, respectively (Table 2). Overall, 55% of patients
were sensitized to at least one of the six examined food
Table 1 Characteristics of the population sample
All
(N = 1360)
North
(N = 405)
Center
(N = 672)
South and Islands
(N = 283) p*
Males (n, %) 920 (67.6) 270 (66.7) 465 (69.2) 185 (65.4) ns
Age (years) (mean, SD) 10.5 (3.4) 10.5 (3.5) 10.5 (3.4) 10.2 (3.4) ns
Siblings 1006 (74) 264 (65.2) 500 (74.4) 242 (85.5) <0.001
Older (n, %) 499 (36.7) 125 (30.9) 258 (38.4) 116 (41) 0.011
Younger (n, %) 594 (43.7) 167 (41.2) 278 (41.4) 149 (52.7) 0.003
Familial atopy
Father (n, %) 529 (38.9) 182 (44.9) 230 (34.2) 117 (41.3) 0.001
Mother (n, %) 602 (44.3) 195 (48.1) 287 (42.7) 120 (42.4) ns
Smoke exposure
Father (n, %) 538 (39.6) 153 (37.8) 262 (39) 123 (43.5) ns
Mother (n, %) 314 (23.1) 98 (24.2) 163 (24.3) 53 (18.7) ns
Allergic rhinitis (n, %)
Age at onset (years) (mean, SD) 5.3 (2.8) 5.1 (2.6) 5.8 (3.0) 4.4 (2.4) <0.001
Disease duration (years) (mean, SD) 5.2 (3.3) 5.4 (3.4) 4.8 (3.2) 5.8 (3.4) <0.001
Months/year with symptoms (mean, SD) 4.3 (1.8) 3.9 (1.7) 4.3 (2.0) 4.9 (1.3) <0.001
Allergic Rhinitis and its Impact on Asthma
ARIA classification (quality)†
Sneezers (n, %)† 875 (64.3) 173 (42.7) 495 (73.7) 207 (73.1) <0.001
Blockers (n, %)† 169 (12.4) 55 (13.6) 68 (10.1) 46 (16.3)
ARIA classification (severity)
Mild (n, %) 665 (48.9) 262 (64.7) 285 (42.4) 118 (41.7) <0.001§
Intermittent (n, %) 353 (26) 178 (44) 136 (20.2) 39 (13.8)
Persistent (n, %) 312 (22.9) 84 (20.7) 149 (22.2) 79 (27.9)
Moderate–severe (n, %) 695 (51.1) 143 (35.3) 387 (57.6) 165 (58.3)
Intermittent (n, %) 136 (10) 43 (10.6) 81 (12.1) 12 (4.24)
Persistent (n, %) 559 (41.1) 100 (24.7) 306 (45.5) 153 (54.1)
Asthma (n,%) 533 (39.2) 202 (49.9) 232 (34.5) 99 (35) <0.001
Age at onset (years) (mean, SD) 5.0 (3.1) 4.9 (2.9) 5.4 (3.4) 3.9 (2.6) <0.001
GINA classification‡
Intermittent (n, %) 327 (24) 119 (29.4) 147 (21.9) 61 (21.6) 0.001
Mild persistent (n, %) 72 (5.29) 20 (4.94) 47 (6.99) 5 (1.77)
Moderate persistent (n, %) 62 (4.56) 25 (6.17) 27 (4.02) 10 (3.53)
Severe persistent (n, %) 33 (2.43) 19 (4.69) 6 (0.89) 8 (2.83)
Control
Good (n, %) 106 (7.79) 35 (8.64) 52 (7.74) 19 (6.71) ns
Partial (n, %) 210 (15.4) 86 (21.2) 88 (13.1) 36 (12.7)
Uncontrolled (n, %) 217 (16) 81 (20) 92 (13.7) 44 (15.5)
Other allergy symptoms
Oral allergy syndrome (n, %) 325 (23.9) 125 (30.9) 153 (22.8) 47 (16.6) <0.001
Anaphylaxis (n, %) 77 (5.66) 36 (8.89) 25 (3.72) 16 (5.65) 0.002
Urticaria/angioedema (n, %) 270 (19.9) 114 (28.1) 82 (12.2) 74 (26.1) <0.001
Atopic dermatitis (n, %) 488 (35.9) 202 (49.9) 156 (23.2) 130 ((45.9) <0.001
Gastrointestinal symptoms (n, %) 90 (6.62) 45 (11.1) 26 (3.87) 19 (6.71) <0.001
*Chi-square test was used comparing frequencies; ANOVA test comparing means.
†Three hundred and sixteen patients could not be classified neither as sneezers nor as blockers according to Allergic Rhinitis and its Impact on
Asthma (ARIA) criteria.
‡In 39 subjects, asthma could not be classified according to Global Initiative for Asthma (GINA) criteria due to missing values.
§Mild vs. moderate–severe.
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extracts (apple, peach, wheat, soy, peanut, hazelnut). The
most frequent skin reaction on SPT was observed against
peanuts (30%) and hazelnuts (25%). About one-fourth of the
patients reacted to date palm profilin, while only a tiny
fraction (2%) was sensitized to latex. The number of positive
SPT reactions was higher among the patients sensitized than
in those not sensitized to profilin (8.6  3.0 vs. 5.1  2.9;
p < 0.001).
Geographic differences
Statistically significant differences across geographic areas were
identified (Table 1). Children recruited in Northern Italy had
more frequently asthma and OAS comorbidity and a lower
frequency of moderate-to-severe disease (Table 2, Fig. 2),
while those recruited in the Southern regions had an earlier
disease onset and a longer disease duration. The mean number
of months with symptoms during the year grew with a north-
south gradient from 3.9 (SD  1.7) months in the North to 4.9
(SD  1.3) months in the South (p < 0.001). Accordingly, in
Southern Italy the springtime extension of AR symptoms was
longer (Fig. 1b). Patients recruited in Northern Italy were
more frequently sensitized to the pollens of Phleum pratense,
Cynodon dactylon, birch, hazel, and ragweed. Similarly, poly-
sensitization to pollens and sensitization to date palm profilin,
peanut, hazelnut, and soybean were more common in the
North. By contrast, skin sensitization to olive, cypress, and
pellitory pollens was more frequent in Central and Southern
Italy (Table 2, Fig. 2).
Factors affecting the severity of pollen-induced AR
A univariate analysis was used to search for risk factors of a
higher severity of symptoms (moderate-to-severe AR) and of
asthma or OAS comorbidity. A few risk factors, including age,
older siblings, a smoking father, a longer disease duration since
onset, and a broader seasonal duration of symptoms, were
associated with moderate-to-severe pollen-induced AR; an
atopic mother, earlier disease onset, longer disease duration
since onset, a broader seasonal duration of symptoms, and a
‘blocker’ phenotype were associated with asthmatic comorbid-
ity; last, male gender, smoking parents, and a longer disease
duration since onset were associated with OAS in univariate
analysis (Table 3).
Months with symptoms of allergic rhinis (seasonality)
(a) (b)
(c) (d)
Figure 1 Frequency distribution of different parameters in a population of 1360 children affected by pollen-induced allergic rhinoconjunctivitis
(AR) and/or asthma: (a) duration of AR (years); (b) months with symptoms, by geographic areas; (c) lifetime immediate food reactions as reported
by patients, parents, and/or caregivers (d) number of sensitizations for pollens and foods.
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A stepwise regression analysis was then performed to
ascertain whether some of the above-mentioned factors were
primarily associated with the markers of severity of pollen-
induced AR (Table 4). In this model, each year of disease
duration since onset was associated with higher odds of
moderate-to-severe pollen-induced AR (OR 1.06, 95% CI
1.02–1.11; p 0.004), asthma comorbidity (OR 1.05, 95%
CI 1.00–1.09; p 0.030), and OAS comorbidity (OR 1.08, 95%
CI 1.04–1.12; p < 0.001). In keeping with the stepwise regres-
sion analysis, we observed that the risks of more severe pollen-
induced AR, asthma, and OAS comorbidity, as well as a
broader duration of seasonal symptoms, and polysensitization
were all increasing with the duration of pollen-induced AR
since its reported onset (Fig. 3).
Discussion
We examined 1360 children with pollinosis seeking care at 16
Italian pediatric allergy centers and who had never received
SIT for their disease. Our major findings include the following:
(i) a quite long average reported disease duration (over 5 yr at
recruitment); (ii) a high frequency of moderate-to-severe
disease (51%), asthma comorbidity (39%), OAS (24%), and
a very high degree of heavy polysensitization (≥6 positive SPT)
(53%); (iii) an association between longer disease duration
from its onset and the selected markers of disease severity; (iv)
a higher severity and a broader extension of symptoms in
Southern Italy, balanced by a more frequent birch and plant-
derived food sensitization as well as of OAS and asthma in
Northern Italy. These data indicate that pollen-induced AR is
in an advanced stage in a large proportion of children seeking
care at the participating Italian allergy centers. They also may
imply that, for many of these patients, a long time-lag might
have occurred between disease onset and the clinical evaluation
by a specialist.
In this study, we have used many different markers of
disease severity: a validated classification (ARIA), asthma and
OAS comorbidity, the extension of the seasonal period with
symptoms, and the number of pollens eliciting a positive skin
wheal reaction. All these parameters consistently showed that
the level of severity of pollen-induced AR in the study
population is high. A longitudinal study (15) has recently
shown that the immunologic response causing pollen-induced
AR is a progressive process starting simple and becoming more
intense and complex with time. Therefore, it may be speculated
that, for many patients, the disease would have been less severe
if they had been referred to the specialized centers immediately
after the onset of their pollen-induced AR and not after many
Table 2 Atopic sensitization to airborne and vegetable food allergens in 1360 Italian children
Allergenic extract
All
(N = 1360) %
North
(N = 405) %
Center
(N = 672) %
South & Islands
(N = 283) % p*
Pollen
P. pratense 89.6 95.1 90.6 79.5 <0.001
C. dactylon 70.2 80.7 71.1 52.7 <0.001
Olive tree 59.6 51.6 63.4 62.2 <0.001
P. lanceolata 58.8 70.1 55.1 51.6 <0.001
C. album† 64.4 69.4 68.9 50.5 <0.001
Cypress 41.4 23.7 55.5 33.2 <0.001
Birch 37.1 49.1 34.7 25.8 <0.001
Plane 34.2 36.1 34.8 30.0 0.233
Pellitory 34.3 19.8 37.8 46.6 <0.001
Hazel† 39.9 54.1 36.7 24.7 <0.001
Mugwort 24.4 26.9 19.2 33.2 <0.001
Salsola† 25.1 31.1 22.0 20.9 0.002
Ambrosia† 22.5 27.4 22.1 15.9 0.002
Holm† 7.7 12.5 5.1 4.6 <0.001
≥3 pollens† 83.5 87.2 83.6 77.7 0.005
≥6 pollens† 49.3 58.0 46.3 44.2 <0.001
Food
Peanut 30.0 34.6 26.9 30.7 0.029
Hazelnut 25.6 36.1 20.1 23.7 <0.001
Peach 19.6 12.6 16.1 37.8 <0.001
Wheat 18.8 26.4 8.9 31.1 <0.001
Apple 15.8 10.4 14.0 27.9 <0.001
Soybean 8.7 14.6 5.8 7.1 <0.001
≥3 foods 18.8 21.23 13.8 26.86 <0.001
Profiline 24.9 34.3 21.6 19.1 <0.001
Latex† 1.9 1.5 2.3 1.8 0.666
*p-value is referred to the comparison among Northern, Central and Southern Italy.
†All (n = 1110), Center (n = 422).
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years. Accordingly, the observed associations suggest that in
most children the disease process had had enough time to
become more and more complex through the years before their
participation to this study. It could be also argued that these
patients should have been treated earlier in the attempt to
prevent their disease progression, both to prevent asthma (16)
and to possibly block the biologic process that enhances the
allergic sensitization to different sources and thus also induce
OAS, even if the latter point needs more studies to be proven.
In our study, about every fourth child suffered from OAS
(Table 1). This high prevalence was paralleled by a high
prevalence of sensitivity to profilin, as reported in Table 2.
Therefore, we tend to consider this high OAS prevalence a
genuine one, rather than due to overreporting of symptoms.
OAS is more frequent in adults but is also becoming more and
more common in children with pollen allergy (17). Our
observation may be consistent with the overall raising trend
of food allergies, now known as ‘the second wave of the allergy
epidemic’ (18). We speculate that OAS is not only becoming
more frequent, but also that its onset (once more typical of
adulthood) is being anticipated to childhood. To our knowl-
edge, no observational longitudinal studies have so far exam-
ined the incidence of OAS in pollen-allergic children. On the
other hand, one of us has shown that SIT may treat OAS in
birch-allergic patients (19), and this observation has been
replicated in some trials, but not in others. By contrast, no
intervention study has addressed the hypothesis that early
treatment (with SIT) can prevent the onset of OAS in children.
In Italy, the role of environmental factors as determinants
for AR has recently been confirmed by an epidemiological
study in which female gender, environmental smoke exposure,
mold/dampness exposure, traffic exposure, current asthma,
eczema, and the highest atopy index classes are significant risk
factors for the disease (20). In the present analysis, we found
also remarkable geographic differences in the frequencies of
sensitization to birch and ragweed (higher in Northern Italy)
Figure 2 Map of Italy showing the location of the recruiting centers and the differences across the country (North, Center, South, and Islands).
Left graphs: clinical features. Right graphs: sensitization examined with SPT.
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Table 3 Relationship of risk factors with higher symptom severity, asthma and oral allergy syndrome (OAS) comorbidities in 1360 Italian
children with pollen allergic rhinoconjunctivitis
Mild
(N = 665)
Moderate or
severe
(N = 695) p
No asthma
(N = 827)
With asthma
(N = 533) p
No OAS
(N = 1035)
With OAS
(N = 325) p
Males (n, %) 451 (68) 469 (67) ns 558 (67) 362 (68) ns 723 (70) 197 (61) 0.002
Age (years)
(mean, SD)
10.1 (3.4) 10.8 (3.4) <0.001 10.4 (3.5) 10.5 (3.3) ns 10.3 (3.4) 10.9 (3.6) 0.003
Siblings 614 (74) 392 (74) ns 774 (75) 232 (71) ns
Older (n, %) 211 (32) 288 (41) <0.001 302 (37) 197 (37) ns 379 (37) 120 (37) ns
Younger (n, %) 296 (45) 298 (43) ns 366 (44) 228 (43) ns 462 (45) 132 (41) ns
Familial atopy
Father (n, %) 269 (40) 260 (37) ns 310 (37) 219 (41) ns 392 (38) 137 (42) ns
Mother (n, %) 289 (43) 313 (45) ns 348 (42) 254 (48) 0.043 445 (43) 157 (48) ns
Smoke exposure
Father (n, %) 244 (37) 401 (58) 0.034 324 (39) 214 (40) ns 394 (38) 144 (44) 0.045
Mother (n, %) 141 (21) 173 (25) ns 179 (22) 135 (25) ns 218 (21) 96 (30) 0.002
Allergic rhinitis (n, %)
Age at onset
(years) (mean, SD)
5.2 (2.6) 5.3 (3.1) ns 5.6 (3.0) 4.8 (2.5) <0.001 5.3 (2.7) 5.2 (3.1) ns
Disease duration
(years) (mean, SD)
4.9 (3.4) 5.4 (3.3) 0.006 4.8 (3.2) 5.8 (3.4) <0.001 5.0 (3.3) 5.8 (3.4) <0.001
Months/year with
symptoms (mean, SD)
3.9 (1.7) 4.6 (1.8) <0.001 4.2 (1.7) 4.4 (2.0) 0.014 4.3 (1.8) 4.4 (1.8) ns
Allergic Rhinitis
and its Impact
on Asthma
classification (quality)*
Sneezers (n, %) 352 (82) 523 (85) ns 548 (87) 327 (79) <0.001 661 (64) 214 (66) ns
Blockers (n, %) 75 (18) 94 (15) 81 (13) 88 (21) 125 (12) 44 (14)
*Three hundred and fifteen patients could not be classified, of which 197 among not asthmatics and 118 among asthmatics.
Table 4 Multivariate analysis of the relationships between risk factors and markers of pollen allergic rhinoconjunctivitis (AR) severity in Italian
children
Moderate-to-severe AR
(n = 1360)
Asthma
(n = 1044)
Oral allergy syndrome
(n = 1359)
OR 95% CI p OR 95% CI p OR 95% CI p
Age at onset of AR (years) 1.05 1.00, 1.086 0.043 0.92 0.87, 0.97 0.001 –
Duration of AR since onset (by year) 1.06 1.02, 1.096 0.004 1.05 1.00, 1.09 0.030 1.08 1.04, 1.12 <0.001
Sneezers* – 1.00 –
Blockers† – 1.54 1.09, 2.18 0.015 –
Central Italy 1.00 1.00 1.00
Northern Italy 0.42 0.33, 0.55 <0.001 2.6 1.88, 3.6 <0.001 1.43 1.08, 1.89 0.014
Southern Italy 0.9 0.67, 1.21 ns 0.82 0.59, 1.14 0.236 0.63 0.42, 0.9 0.012
Older siblings† 1.40 1.11, 1.77 0.004 – –
Months/year with symptoms 1.23 1.14, 1.31 <0.001 – –
Smoke father 1.23 0.98, 1.54 <0.001 – –
Smoke mother – – 1.54 1.16, 2.06 0.003
Female – – 1.57 1.2, 2.05 0.001
Variables included in the model after stepwise regression.
*Included only in the rhinitis model.
†Included only in the asthma model.
Number of observations = 1044; LR v2 = 84.86; p > v2 = 0.0000; Pseudo R2 = 0.0605.
OR, odd ratio
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and to pellitory and olive (higher in Southern Italy): these
differences confirm previous observations, reflecting the
distribution of trees and weeds species from Northern to
Southern Italy and at a European, continental level (21). Not
surprisingly, these differences are paralleled by differences in
the frequency of OAS (higher in Northern Italy) and in the
seasonal symptoms extension (longer in Southern Italy). Thus,
different pollen exposures may explain why the markers of
‘severity’ slightly differ in Northern Italy (OAS, food-pollen
syndrome) from Southern Italy (higher intensity and longer
season of respiratory symptoms). To our knowledge, no other
pediatric study has examined similar North-South gradients at
country level in Europe and linked to markers of disease
severity or comorbidities. Geographic differences of sensitiza-
tion patterns in patients with respiratory allergies have been
reported in Spain (22) or France (23), but they focused on coast
vs. continental areas rather than a North-South gradient.
Given its geographic characteristic (a country elongated from
North to South), Italy can reproduce better than other
countries the North-South gradients typically observed, on a
wider scale, at European level.
The present analysis shows also that only a tiny minority
of the patients (6%) are pollen-monosensitized. This may
have a consequence on the propensity to prescribe SIT.
Recent trials showed that SIT can be effective also in pollen-
polysensitized patients (24, 25). Nevertheless, guidelines do
not recommend the administration of mixtures of different
allergenic sources (26), and polysensitization is still seen by
many allergists as a contraindication to SIT treatment. It
could be therefore argued that many of these children would
have been treated with SIT if they had seen the allergist at an
earlier, mono or oligo-sensitized disease stage. On the other
hand, sensitization to profilin is very frequent (25%) in the
examined population. Thus, sensitization to profilin or other
highly cross-reactive ‘panallergens’ may contribute to explain
this high frequency of heavy polysensitization (27). An
obvious consequence is the need to discriminate ‘genuine’
from ‘false’ sensitizations by allergy testing based on spe-
cies-specific molecules, a diagnostic approach essential for
appropriate SIT prescription (28).
Our study might be influenced by some limitations. First,
the population sample is not representative of the general
population of children examined by allergy specialists in Italy,
and although the population sample is very large, the
generalizability of our conclusions may be questioned.
Second, the data of age at disease onset and the consequent
calculation of disease duration were obtained retrospectively
in this cross-sectional study and therefore subject to potential
recall bias. This bias is often associated with a so-called
‘telescope’ effect, i.e., the tendency to postpone the events that
occurred many years before. Third, reported asthma and OAS
or other food allergies could not be confirmed by lung
function tests or by challenge tests, respectively, so that
overreporting cannot to be excluded. However, we believe
that any misdiagnosis of asthma or OAS would have
contributed to confound, rather than to generate the observed
associations. Fourth, sensitization to perennial allergens
(house dust mites, molds, domestic animals) might have
influenced the severity of pollen AR and asthma. Neverthe-
less, we argue that any misclassification of cases would have
confounded, rather than strengthened the observed associa-
tions. On the other hand, our study has several strengths,
such as the quite large population size, the broad distribution
of the participating centers across Italy, the use of interna-
tionally validated diagnostic criteria and definitions, and the
adoption of a common electronic platform and standardized,
high-quality reagents.
In conclusion, this nationwide study demonstrates that
pollen-induced AR is in an advanced stage in many children
who had never received SIT against pollen and who sought
care from Italian allergy clinics. The observed association
between markers of pollen-induced AR severity and its
duration needs to be confirmed in longitudinal studies and
raises the question whether this disease and its underlying
immunologic processes should be diagnosed and treated
earlier in life. Our study suggests that countrywide plans for
early diagnosis and intervention (already started in other
European countries) (29) should be planned also in Italy and
adapted to the different epidemiological characteristics of its
macro-areas.
Figure 3 Probability of having moderate-to-severe allergic
rhinoconjunctivitis (AR), asthma, polysensitization, and longer
extension of symptoms during a year among children with AR, by
the duration since onset of their AR.
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